Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer

• Verfasst von: Huber, Rudolf M. [VerfasserIn]
• Verfasst von: Reck, Martin [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Titel: Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer
• Verf.angabe: Rudolf M. Huber, Martin Reck and Michael Thomas
• E-Jahr: 2013
• Jahr: September 30, 2013
• Umfang: 15 S.
• Fussnoten: Gesehen am 02.11.2021
• Titel Quelle: Enthalten in: The European respiratory journal
• Ort Quelle: Lausanne : ERS, 1988
• Jahr Quelle: 2013
• Band/Heft Quelle: 42(2013), 4, Seite 1119-1133
• ISSN Quelle: 1399-3003
• DOI: doi:10.1183/09031936.00143112
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1775869539

Abstract

Stage III nonsmall cell lung cancer (NSCLC) encompasses a heterogeneous group of patients, some of whom may be candidates for potentially curative surgery, although for the majority surgery is not an option. Recommended therapy for patients with unresectable stage III disease is concurrent treatment with chemotherapy and thoracic radiotherapy, although even with this dual modality therapy survival remains disappointing. Novel classes of agents including targeted therapies have been shown to improve survival in advanced stage NSCLC, raising the possibility that these agents may have benefits in multimodal therapy when combined with chemoradiotherapy. Here we consider the rationale for combining new agents with chemoradiotherapy and the evidence from clinical studies assessing multimodal strategies for the management of patients with unresectable stage III NSCLC. - Tweetable abstract @ERSpublications - click to tweetThe rationale for combining new agents with chemoradiotherapy to treat stage III NSCLC and data from clinical studies http://ow.ly/nuE1d